# Xiidra vs. Xiidra + Dextenza Treatment for Dry Eye Disease

> **NCT04413253** · PHASE4 · TERMINATED · sponsor: **Eye Surgeons of Indiana** · enrollment: 5 (actual)

## Conditions studied

- Dry Eye Syndromes

## Interventions

- **DRUG:** Lifitegrast 5% Ophthalmic Solution
- **DRUG:** Dexamethasone Intracanalicular Insert, 0.4mg with Lifitegrast 5% Ophthalmic Solution

## Key facts

- **NCT ID:** NCT04413253
- **Lead sponsor:** Eye Surgeons of Indiana
- **Sponsor class:** NETWORK
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-08-01
- **Primary completion:** 2022-04-11
- **Final completion:** 2022-04-11
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** Unable to recruit
- **Last updated:** 2022-04-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04413253

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04413253, "Xiidra vs. Xiidra + Dextenza Treatment for Dry Eye Disease". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04413253. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*